The implant clinician prescribed antibiotics (name, frequency, dosage unknown) to control the infection and cleaned the area with antibiotic solution.The implanting clinician mentioned to the clinical representative that the patient has multiple conditions that may have contributed to the infection since the patient has type 2 diabetes and a hernia, which may have contributed to the erosion and the infection by pushing the leads the surface of the skin.A stimwave representative conducted a review of sterilization and packaging records for the respective product lot; stimwave has confirmed that the product was delivered sterile, validated sterilization parameters were used, and sterile barriers were verified to be intact following packaging.Based on this information, the infection/erosion was confirmed/replicated.There is no evidence that the product did not meet specifications, and the stimulator is used for the treatment of pain.The cause of the infection/erosion is due to preexisting patient conditions and the stimulator being placed at an off-label location.Design fmea for stimq 06-01233 and hra for stimq 06-01232 was reviewed and infection/erosion are known issue with mitigation controls in place to reduce risk as far as possible and no corrective action is required.Stimwave's global device erosion rate: (b)(4).Stimwave's global infection rate: (b)(4).The frequency is occasionally and the impact is important.
|